39802-78-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-CHLOROPHENYL)BENZALDEHYDE is used as a synthetic reagent for the development of novel compounds with potential pharmaceutical applications. Its unique structure allows for the creation of various derivatives that can be tested for their biological activities, such as antimicrobial, anticancer, or anti-inflammatory properties.
Used in Chemical Synthesis:
In the field of organic chemistry, 4-(2-CHLOROPHENYL)BENZALDEHYDE serves as a key intermediate in the synthesis of complex organic molecules. Its reactive sites, including the aldehyde group and the chlorine atom, can be further functionalized to produce a wide range of chemical products.
Used in Antimicrobial Applications:
4-(2-CHLOROPHENYL)BENZALDEHYDE is used as a reagent in the synthesis and screening of cyanopyrans, which are compounds with antimicrobial activities. These cyanopyrans can be evaluated for their potential to combat various microbial infections, making them valuable in the development of new antimicrobial agents.

Upstream product

• 109524-03-0 2'-chlorobiphenyl-4-ylmethanol 
• 3808-93-3 2'-chloro[1,1'-biphenyl]-4-carboxylic acid 
• 89900-96-9 2'-chlorobiphenyl-4-carboxylic acid methyl ester 
• 694-80-4 2-bromo-1-chlorobenzene 
• 87199-17-5 4-formylphenylboronic acid, 
• 3900-89-8 2-Chlorobenzeneboronic acid 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 57592-01-5 (E)-4-(2'-chloro-4-biphenylyl)-3-buten-2-one 
• 39802-79-4 4-(2'-chlorophenyl)cinnamic acid 
• 726136-65-8 2'-chloro-N-methyl-[1,1'-biphenyl]-4-methanamine 
• 1144106-48-8 C₂₁H₁₈ClNO 
• 516481-29-1 2-[4-(2-Chloro-phenyl)-phenyl]-1H-benzoimidazole-5-carboxylic Acid Amide 

Relevant academic research and scientific papers

Gold Catalysts Can Generate Nitrone Intermediates from a Nitrosoarene/Alkene Mixture, Enabling Two Distinct Catalytic Reactions: A Nitroso-Activated Cycloheptatriene/Benzylidene Rearrangement

Gold-catalyzed reactions of cycloheptatrienes with nitrosoarenes yield nitrone derivatives efficiently. This reaction sequence enables us to develop gold-catalyzed aerobic oxidations of cycloheptatrienes to afford benzaldehyde derivatives using CuCl and nitrosoarenes as co-catalysts (10-30 mol %). Our density functional theory calculations support a novel nitroso-activated rearrangement, tropylium → benzylidene. With the same nitrosoarenes, we developed their gold-catalyzed [2 + 2 + 1]-annulations between nitrosobenzene and two enol ethers to yield 5-alkoxyisoxazolidines using 1,4-cyclohexadienes as hydrogen donors.

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease

Monoamine oxidase-B (MAO-B) is a well-established therapeutic target for Parkinson’s disease (PD); however, previous clinical studies on currently available irreversible MAO-B inhibitors have yielded disappointing neuroprotective effects. Here, we tested the therapeutic potential of KDS2010, a recently synthesized potent, selective, and reversible MAO-B inhibitor in multiple animal models of PD. We designed and synthesized a series of α-aminoamide derivatives and found that derivative KDS2010 exhibited the highest potency, specificity, reversibility, and bioavailability (> 100%). In addition, KDS2010 demonstrated significant neuroprotective and anti-neuroinflammatory efficacy against nigrostriatal pathway destruction in the mouse MPTP model of parkinsonism. Treatment with KDS2010 also alleviated parkinsonian motor dysfunction in 6-hydroxydopamine-induced and A53T mutant α-synuclein overexpression rat models of PD. Moreover, KDS2010 showed virtually no toxicity or side effects in non-human primates. KDS2010 could be a next-generation therapeutic candidate for PD.

PIPERIDINES USEFUL FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

The invention relates to compounds which are substituted chiral or achiral derivatives of 3- or 4- aminopiperidine of the general formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula I and especially their use as inhibitors of β-secretases.

SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER’S DISEASE

The invention relates to novel compounds, which are substituted chiral or achiral derivatives of 3- or 4- aminomethylpiperidine of the general formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula (I) and especially their use as inhibitors of beta-secretases for the treatment of Alzheimer’s disease.

Comparison of the Properties of Liquid Crystals Derived from Certain Lateral Halogeno-substituted Azomethines

Twenty-eight 4-n-alkoxy-N-(2- and 2'-halogenobiphenyl-4-ylmethylene)anilines comprising 4,8,8,4, and 4 members derived , respectively, from 2-fluoro-, 2'-fluoro-, 2'-chloro-, 2'-bromo-, and 2'-iodo-biphenyl-4-carbaldehyde, together with six 4-p-n-alkoxy-2'-fluorobenzylideneaminobiphenyls have been prepared.The liquid crystal behaviour of these compounds has been compared with analogous azomethines with reversed CH=N linkage, previously reported.